-

Voxeleron Appoints New CEO and Secures Funding to Continue Growing Its Innovative Ophthalmic Image Analysis Platform

Seasoned life science industry veteran to drive the next phase of growth and market expansion

AUSTIN, Texas--(BUSINESS WIRE)--Voxeleron, a cloud-based ophthalmic image analysis platform provider, today announced the appointment of Joanna Williams as its new Chief Executive Officer (CEO). With over 25 years of experience in the life sciences industry, Williams brings a wealth of expertise in business growth, service expansion and operational delivery. She was most recently a Co-founder and Chief Operating Officer at Lexitas, a preeminent ophthalmology Contract Research Organization (CRO). Her career trajectory also includes leadership roles at ICON Clinical Research, where she led the growth of their clinical technology business unit and spearheaded initiatives in operational excellence.

"We are delighted to welcome Joanna Williams to the Voxeleron team as our new CEO. Her impressive track record at Lexitas, and her experience at ICON, a global leader in clinical research services, makes her the perfect choice to guide our company through its next phase of growth," said Jonathan Oakley, Co-founder of Voxeleron. “Her background in clinical trials is the perfect complement to Voxeleron’s innovative technology expertise.”

In addition to this leadership appointment, Voxeleron has secured funding to fuel the company's expansion efforts and support ongoing research and development initiatives. This infusion of capital will enable Voxeleron to scale operations and explore new market opportunities.

"We are at the forefront of the industry with innovative device-agnostic solutions that bring much-needed speed, accuracy, and versatility to ophthalmic clinical trials,” said Joanna Williams, CEO of Voxeleron. "I am excited to lead Voxeleron during this pivotal moment and look forward to working closely with the team to drive continued success and impact."

Voxeleron will be showcasing its platform of AI-enabled ophthalmic image analysis tools at the upcoming ARVO 2024 Conference on May 5-9 in Seattle, Washington. To schedule a meeting or demo, visit Voxeleron's website.

About Voxeleron

Voxeleron is the innovative leader in AI-backed ophthalmic image analysis, delivering a powerful platform that interprets millions of measurements across multiple formats to translate clinical research data into valid, actionable results. By optimizing all aspects of clinical eye research, from initial trial recruitment through post-hoc analysis, Voxeleron is bringing comprehensive eye health into focus and helping eradicate diseases affecting tens of millions. Learn more at voxeleron.com.

Contacts

Cristi Jakubik
Marketing
cristi@launch-marketing.com
512.495.9900

Voxeleron


Release Summary
Voxeleron, a cloud-based ophthalmic image analysis platform provider, announced the appointment of Joanna Williams as its new Chief Executive Officer.
Release Versions

Contacts

Cristi Jakubik
Marketing
cristi@launch-marketing.com
512.495.9900

More News From Voxeleron

Voxeleron’s Orion Ophthalmic Image Analysis Platform Reduces Variability of Clinical Trial Outputs

AUSTIN, Texas--(BUSINESS WIRE)--Voxeleron, a cloud-based ophthalmic image analysis platform provider, announced today the results of a study demonstrating its Orion platform delivers higher accuracies and reduced variability when compared to original equipment manufacturer (OEM) software from Carl Zeiss Cirrus and Heidelberg Spectralis. The study used Orion to analyze optical coherence tomography (OCT) images from the two manufacturers and clearly showed greater accuracy while reducing variabil...

Voxeleron Launches iNebula™, a Cloud-Based Platform for Optimized Ophthalmic Clinical Trial Workflow

SAN FRANCISCO--(BUSINESS WIRE)--Voxeleron, a cloud-based platform provider that analyzes and tracks all formats of ophthalmic data, today announced the availability of iNebula, a digital media platform specifically developed to optimize ophthalmic clinical trial management. With iNebula, clinical research organizations (CROs), reading centers, and pharmaceutical sponsors can view comprehensive trial data and status in real time. iNebula’s unique manufacturer-neutral platform works seamlessly ac...
Back to Newsroom